



Optibrium Supports Global Health through Academic and Not-for-Profit Consortium

Access to StarDrop™ will support development of new treatments for neglected diseases via Global Health Programme

CAMBRIDGE, UK, 9 February, 2016 – Optibrium™, a developer of software for small molecule drug discovery and optimisation, today announced it will make its StarDrop™ technology available to an international consortium of academic and not-for profit organisations. Under the agreement, licensed access to StarDrop software will be provided to support drug discovery projects as part of a global health programme focused on developing new treatments for neglected diseases.

Consortium partners are involved in projects to facilitate and speed up the development of therapies for the treatment of so-called “neglected” diseases such as leishmaniasis, sleeping sickness, Chagas disease, malaria, tuberculosis and paediatric HIV. StarDrop’s unique optimisation and compound selection capabilities will help researchers to efficiently focus their efforts on researching candidate drugs with the best chance of success in becoming effective therapies in the treatment and prevention of these diseases.

Dr Matthew Segall, Optibrium’s CEO, commented, “We are very proud to support such an important effort to address some of the world’s biggest health issues. Drug development is enormously time consuming, expensive and high risk, due to the challenge of finding high quality candidate drugs with the right balance of efficacy and safety. By adopting StarDrop, consortium partners will have global access to a wide range of tools allowing their researchers to quickly target compounds with the highest chance of success and avoid missed opportunities.”

Neglected diseases continue to cause significant morbidity and mortality in the developing world. Of 850 new therapeutic products approved between 2000 and 2011, only 4% (and only 1% of all approved NCEs) were indicated for neglected diseases, even though these diseases account for 11% of the global disease burden ^[1].

Partner organisations included in the agreement are: Anacor, Broad Institute, Epichem, Infectious Disease Research Institute (IDRI), Medicines for Malaria Venture (MMV), Sandexis, TB Alliance, UNICAMP, University of California San Diego, University of Cape Town, University of Dundee and University of Liverpool.

For further information on Optibrium or StarDrop, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

^[1] *Pedrique et al. The drug and vaccine landscape for neglected diseases (2000-2011): a systematic assessment The Lancet 2013; 1(6) e371–e379*

ENDS

Media contact

Sarah Jeffery

Zyme Communications

E-mail: sarah.jeffery@zymecomunications.com

Phone: +44 (0) 7771 730919

Optibrium

Nick Foster

Director, Business Development

E-mail: nick.foster@optibrium.com

Phone: +44 (0)1223 815900

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's portfolio of products includes:

- StarDrop™, which brings confidence to the selection and design of high quality candidate compounds. StarDrop creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective candidate compounds with a high probability of success downstream.
- Sentira™, an easy-to-use, dynamic data visualisation platform that helps to quickly spot patterns in compound data, analyse structure-activity relationships and elegantly present and report results.
- Asteris™, an iPad app that enables researchers to explore new compound ideas when and where they want, by combining highly intuitive chemistry drawing tools with StarDrop's visually informative predictive modelling.

Founded in 2009, Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

Visit the online community at <http://www.optibrium.com/community/> for further discussions on improving the productivity of drug discovery.